PureTech Ventures received FDA approval for its medicines on July 9, 2025. Raju Kucherlapati and Robert Langer were involved in the company's board.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PureTech Ventures received FDA approval for its medicines on July 9, 2025. Raju Kucherlapati and Robert Langer were involved in the company's board.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
PureTech Ventures
american company
Nothing else this week.
Related events
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Amy Brenner hopes that a favorable FDA ruling will allow for more peptide products, noting her offices are in Kenwood and Mason.
- FDA approval enables commercial opportunity involving CBRE Group.
- Adam Fisher was appointed as a director in the FDA's Office of Pharmaceutical Quality.
Coverage
Newest first; wire copies grouped- Business WirePureTech Announces Board Change BOSTON, July 08, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated